While many have heard the headlines surrounding Johnson & Johnson (JNJ 0.01%) and problems with its metal hip replacements, the company's subsidiary Ethicon has more than 2,000 lawsuits pending concerning a different medical device -- vaginal mesh, which is used to give support to a patient's pelvic organs in cases of pelvic organ prolapse. In this video, Motley Fool health care bureau chief Brenton Flynn tells investors how much money could be at stake here for the company, and whether this is news to care about or just noise.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Is This Johnson & Johnson Court Case News or Noise?
NYSE: JNJ
Johnson & Johnson

Is this litigation going to be a big deal for Johnson & Johnson?
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.